AMYLOIDOSIS MONTH


 

πŸ…5 Best Papers
πŸ’–Tips, Tricks & Thread
πŸ”΄Diagnostic delays➡️3 years from symptom onset
πŸ‘« may be evaluated > 5 specialists prior to receiving the correct diagnosis
✅vast majority of cardiac amyloidosis➡️transthyretin amyloidosis or light chain amyloidosis
✅“red flag”🚩suspicion for this diagnosisπŸ‘‡
πŸ’ŸECG⬇️voltage QRS amplitude limb leads (≤0.5 mV), pseudo-infarct pattern & relative⬇️voltage QRS (S wave in V1 + Rwave in V5 or V6 ≤15 mm) in the setting of LVH on #EchoFirst AV block
πŸ’ŸEcho concentric LVH, biatrial⬆️& small pericardialπŸ’¦, apical sparing of LV strain
πŸ’Ÿ#whyCMR Diffuse, subendocardial LGE. T1 mapping techniques & measurement of extracellular volumes
πŸ’Ÿ#CVnuc TTR-CA➡️91% sens & nearly 100% spec in the absence➡️monoclonal gammopathy
πŸ’ŸMajority of false➕ tests➡️LC cardiac amyloidosis, exclusion➡️LC amyloidosis is critical
✅Several types of amyloidosis have been described based on the specific protein comprising the deposited fibrils
✅Uncommon for secondary (AA) amyloidosis
to affectπŸ«€& this is rarely seen inπŸ—Ί️where severe chronic inflammatory processes are generally well managed


πŸ”΄Clinical cardiac amyloidosis➡️extracellular deposition of proteins which have folded & aggregated such that they form amyloid fibrils
✅Val122IIe mutation, an hATTR subtype, is highly aggressive & therefore necessitates unique therapeutic and follow up regimens
✅CyBorD ➕ Daratumumab works effectively
to produce responses in AL amyloidosis
🧬Genetic testing➡️critical component of the evaluation
of transthyretin amyloidosis, determining prognosis & treatment
πŸ”΅Val122Ile➡️1st common mutationπŸ‡ΊπŸ‡Έ
πŸ”΅Thr60Ala➡️2nd most common mutationπŸ‡ΊπŸ‡Έ
πŸ”΄Val30Met (pV50M)➡️most common🌏mutation outside of theπŸ‡ΊπŸ‡Έ. Endemic in πŸ‡―πŸ‡΅πŸ‡ΈπŸ‡ͺπŸ‡΅πŸ‡Ή
✅TTR genetic testing is recommended for all patients
with an established diagnosis of ATTR-CA regardless
of ageπŸ§’πŸ‘«πŸ‘΄πŸ§“
✅Once a patient carrying a pathological TTR gene
variant is identified, the predicted age of disease
onset (PADO) should be determined
πŸ”΄Recognizing a constellation of ATTR amyloidosis symptoms➡️suspicion of amyloidosis early in its course
πŸ”΄cardiac, neurologic, nephropathy or musculoskeletal manifestations
πŸ”΄ATTR amyloidosis➡️musculoskeletal manifestations 5 to 15 years prior to other symptoms
🟑Carpal tunnel syndrome🟑Trigger finger🟑Lumbar spinal stenosis
🚩trigger finger➕carpal tunnel syndrome reportedπŸ‡―πŸ‡΅family w/ATTRv
🟑Rupture distal biceps tendon (Popeye sign)🚩>50y
πŸ”΄ATTR amyloidosis is now a treatable disease, recognizing the constellation signs & symptoms, including those that are neurologic & musculoskeletal
πŸ”΄Early treatment will make a meaningful impact on a patient’s quality of life, autonomy, and physical function
πŸ”΄Previously considered a rare disease, CA is increasingly recognized among patients:
✅misdiagnosed as undifferentiated HFPEF
✅paradoxical low-flow/low-gradient aortic stenosis
✅otherwise unexplained left ventricular hypertrophy
πŸ”΄Basis for effective diagnostic & therapeutic
management of CA patients➡️early recognition and
suspicion of possible cases based on clinical red flags,
cardiac imaging, and biomarkers

Comments

Popular posts from this blog

Risk Factors of Lung Cancer

Different Types of Lung Cancer

BLOOD CANCER – TYPES AND TREATMENT